HUTCHMED Receives China NMPA Approval For ORPATHYS In Combination With TAGRISSO For Treatment Of EGFRm NSCLC Patients With MET Amplification After Progression On EGFR Inhibitor Therapy
Benzinga Newsdesk 1 year ago
News
Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —The only all-oral combination treatment option for these
- Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —
- The only all-oral combination treatment option for these patients
- Consistent benefit regardless of first-line EGFR inhibitor therapy —